UNSPSC 51432700: Antihypertensive bicyclo compounds

Antihypertensive drugs made from bridged compounds, two-fused-ring, cyclic hydrocarbons, many of which are -anes, built of cyclohexane and/or cyclopentane, e.g., bicyclo[4.4.0]decANE and bicyclo[2.2.1]heptANE

UNSPSC 51432700 Antihypertensive bicyclo compounds is a Class code under which state and local governments procure emergency medications and pharmaceutical products for fire rescue operations, health and human services programs, and multistate cooperative purchasing agreements. The code sees activity across municipal fire departments, state health agencies, and regional cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions. Recent solicitations show state and local buyers purchasing specific antihypertensive medications — Labetalol HCI vials and Diltiazem vials — alongside complementary advanced life support drugs through sealed-bid processes, as well as broader pharmaceutical procurement frameworks that may encompass antihypertensive compounds within larger generic-medication contracts.

The City of Tampa Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications to be supplied to Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, requiring 370 units of Labetalol HCI 100mg vials and 1,020 units of Diltiazem 25mg vials among other medications, with a one-year base term and optional renewal periods and a Small Local Business Enterprise sheltered-market designation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) in January 2026 with a response deadline of March 26, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) in April 2026 seeking vendor capability information regarding direct-to-manufacturer prescription programs, reflecting early-stage market exploration rather than immediate procurement. Activity spans Florida, Texas, Minnesota, and Oregon jurisdictions, with municipal emergency services, state health agencies, and regional cooperative purchasing alliances as primary buyers.